Hepatitis C virus transmission among HIV-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. by Salazar-Vizcaya, Luisa et al.
  
Hepatitis C virus transmission among HIV-infected men who have sex with men: 
Modeling the effect of behavioral and treatment interventions 
Luisa Salazar-Vizcaya
1,3
 (luisapaola.salazarvizcaya@insel.ch), Roger D Kouyos
2 
(Roger.Kouyos@usz.ch), Cindy Zahnd
1
 (cindy.zahnd@ispm.unibe.ch), Gilles Wandeler
1 3 
(gilles.wandeler@ispm.unibe.ch), Manuel Battegay
4 
(manuel.battegay@usb.ch), Katharine 
Elizabeth Ana Darling
5
 (Katharine.Darling@chuv.ch), Enos Bernasconi
6 
(Enos.Bernasconi@eoc.ch), Alexandra Calmy
7
 (Alexandra.Calmy@hcuge.ch), Pietro 
Vernazza
8
 (pietro.vernazza@kssg.ch), Hansjakob Furrer
3
 (hansjakob.furrer@insel.ch),
 
Matthias Egger
1 9
 (matthias.egger@ispm.unibe.ch), Olivia Keiser*
1 
(olivia.keiser@ispm.unibe.ch), Andri Rauch*
3
(Andri.Rauch@insel.ch), and the Swiss HIV 
Cohort Study  
1
Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland 
2
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, 
Zurich, Switzerland 
3
Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, 
Bern, Switzerland 
4
Division of Infectious Diseases and Hospital Epidemiology University Hospital Basel, Basel, 
Switzerland 
5
Infectious Diseases Service, Department of Medicine, University Hospital and University of 
Lausanne, Lausanne, Switzerland 
6
Division of Infectious Diseases, Lugano Regional Hospital, Lugano, Switzerland 
7
Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland 
8
Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland 
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as
doi: 10.1002/hep.28769
This article is protected by copyright. All rights reserved.
2 
 
 
 
9
 Centre for Infectious Disease Epidemiology & Research (CIDER), University of Cape 
Town, Cape Town, South Africa 
*contributed equally to this manuscript 
Keywords: HCV; MSM; mathematical model; DAAs; sexual behavior. 
  
Page 2 of 53
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
3 
 
 
 
Correspondence to: Olivia Keiser olivia.keiser@ispm.unibe.ch Tel: +41 31 631 35 15 
Fax: +41 31 631 35 20, ISPM, University of Bern, Finkenhubelweg 11, 3012 Bern, 
Switzerland. 
 
Abbreviations: hepatitis C virus (HCV); men who have sex with men (MSM); Swiss HIV 
Cohort Study (SHCS); direct-acting antiviral agents (DAAs) 
Financial support: This study has been financed within the framework of the Swiss HIV 
Cohort Study, supported by the Swiss National Science Foundation (SNF grants #148522 and 
#146143). 
  
Page 3 of 53
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
4 
 
 
 
Abstract  
The incidence of hepatitis C virus(HCV) infections among HIV-infected men-who-have-sex- 
with-men(MSM) increased in recent years and is associated with high-risk sexual behavior. 
Behavioral interventions that target high-risk behavior associated with HCV transmission and 
treatment with direct-acting antivirals(DAAs) may prevent further HCV infections. We 
predicted the effect of behavioral and treatment interventions on HCV-incidence and -
prevalence among HIV-infected MSM up to 2030 using a HCV transmission model 
parameterized with data from the Swiss HIV Cohort Study. We assessed behavioral 
interventions associated with further increase, stabilization and decrease in the size of the 
population with high-risk behavior. Treatment interventions included increase in treatment 
uptake and use of DAAs. If we assumed that without behavioral interventions high-risk 
behavior spread further according to the trends observed over the last decade, and that the 
treatment practice did not change, HCV-incidence converged to 10.7/100 person-years(py). 
All assessed behavioral interventions alone resulted in reduced HCV transmissions. 
Stabilization of high-risk behavior combined with increased treatment uptake and the use of 
DAAs reduced incidence by 77%(from 2.2 in 2015 to 0.5/100 py) and prevalence by 
81%(from 4.8% in 2015 to 0.9%) over the next 15 years. Increasing treatment uptake was 
more effective than increasing treatment efficacy to reduce HCV-incidence and -prevalence. 
A decrease in high-risk behavior, led to a rapid decline in HCV-incidence, independent of 
treatment interventions. Conclusion: Treatment interventions to curb the HCV epidemic 
among HIV-infected MSM are effective if high-risk behavior does not increase as it has 
during the last decade. Reducing high-risk behavior associated with HCV transmission would 
be the most effective intervention for controlling the HCV epidemic, even if this was not 
accompanied by an increase in treatment uptake or efficacy. 
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The HCV epidemic in HIV-infected patients has evolved quickly over the past few years(1-4). 
In western countries, HCV is increasingly transmitted among HIV-infected men who have sex 
with men (MSM)(1, 5-9). We observed, in the Swiss HIV Cohort Study (SHCS)(10), a steep 
rise in incidence of HCV infections among MSM without history of injection drug use. In 
contrast, HCV incidence stabilized among heterosexuals, and decreased among people who 
inject drugs(3).  
 
An international network of HCV transmission among HIV-infected MSM was revealed by a 
phylogenetic study(11). In this population, transmission is associated with high-risk behavior 
including condomless traumatic anal intercourse, fisting, use of recreational drugs, and group 
sex(1, 3, 7, 12, 13). In the SHCS, the increase in HCV incidence coincided with reduced self-
reported condom use among MSM on antiretroviral therapy (ART)(14). 
 
Effective interventions to curb the HCV epidemic among HIV-infected MSM remain to be 
established. Behavioral interventions that target high-risk sexual practices associated with 
HCV transmission may prevent new HCV infections. Because recently introduced treatments 
for HCV with second generation direct-acting antiviral agents (DAAs) rapidly reduce HCV 
viral load and achieve high cure rates, they offer an unprecedented opportunity to prevent 
transmissions. 
 
In this study, we analyzed data from the SHCS to develop a mathematical model of HCV 
transmission among MSM who do not inject drugs. We used the model to replicate the HCV 
epidemic in Switzerland and to estimate the effect of behavioral and treatment interventions 
on HCV incidence and prevalence up to 2030.  
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Subjects and Methods 
The Swiss HIV Cohort Study 
The SHCS is a nationwide, prospective cohort that enrolls HIV-infected patients, aged 16 or 
older, since 1988, drawing from Swiss university hospitals, cantonal reference hospitals and 
private practices(10, 15). Written informed consent is mandatory for inclusion in the SHCS, 
and the study has been approved by all local ethical committees. The SHCS includes 73% of 
HIV-infected patients declared to the Swiss public health authorities (16). Clinical, behavioral 
and laboratory data are collected at enrolment and at follow-up visits every six months. The 
collected data include information on antiretroviral and HCV treatments, sexual preferences, 
condom use and sex with stable and occasional partners(15). HCV-seronegative patients were 
screened biannually for HCV infection between 1998 and 2006, and yearly thereafter. 
Immunoblotting confirmed positive results by third-generation enzyme-linked 
immunoabsorbent assay (ELISA). We included all HCV-seronegative MSM who had at least 
one follow-up HCV antibody measurement after January 2000. Patients with a positive HCV 
serology at entry, those who seroconverted before 2000, and those who reported injecting 
drug use during the follow-up period, were excluded from the incidence analysis. For the 
estimation of the incidence that we used to fit the model, the follow-up period ended at the 
first positive HCV serology or last negative serology as previously described(3). For the 
analyses on sexual behavior, the follow-up period ended at drop-out or death. 
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HCV transmission model 
We adopted a system of ordinary differential equations to model HCV transmission among 
HIV-infected MSM (Supplementary Material). We set out to reproduce HCV incidence 
among HIV-infected MSM in Switzerland between 2000 and 2013 by classifying the 
population into compartments distributed by stage of infection, risk groups and enrolment in 
care. Risk groups included: i) Individuals who do not engage in sexual practices associated 
with HCV transmission (group without high-risk behavior) and ii) Individuals who do engage 
in sexual practices associated with HCV transmission (group with high-risk behavior). Each 
risk group includes five compartments: 1) two HCV-uninfected (Susceptible, S) “in” and 
“out” of HIV care (referred as to in-care and out-of-care from now on); 2) two HCV-infected 
(Infected: I) “in” and “out” of care; and, 3) one on treatment for HCV (on Treatment, T) only 
accessible for individuals in-care. The model structure is summarized in Figure 1. Out-of-care 
individuals can enter the in-care category at a rate ω(t). Newly HIV-infected MSM enter the 
out-of-care susceptible category at a rate that varies over time ρ(t). A fraction φψ(t) of these 
individuals enter the susceptible compartment in the high-risk group, where ψ(t) is the 
proportion of newly HIV-infected MSM who have unprotected sex with occasional partners, 
which we term unsafe sex, and φ is the proportion of these individuals who also engage in 
high-risk behavior and therefore at risk of HCV transmission. High-risk behavior comprises 
condomless traumatic anal intercourse, fisting, use of recreational drugs, and group sex. φ is 
referred to as high-risk/unsafe sex ratio. The remaining newly HIV-infected MSM enter the 
susceptible compartment in the group without high-risk. Individuals switch from the group 
without high-risk to the high-risk group at a rate φσ(t), where σ(t) is the rate at which 
individuals start to have unsafe sex. We refer to ψ(t) and σ(t) as high-risk recruitment 
parameters. All susceptible individuals may be infected by an external force of infection λ 
that accounts for infections unrelated to high-risk contacts within the modeled population. 
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Because λ affects all individuals, incidence is always ≥ λ irrespective of interventions. 
Individuals within the high-risk group infect each other at an infection rate β. This rate is 
associated with the probability of establishing an infection given an infectious contact. 
Infected individuals in both risk groups start treatment at a rate γ(t). The mean duration of 
treatment is 1/η and results in HCV clearance for a fraction α of treated individuals. 
Individuals who clear the infection are again susceptible. Individuals exit the system at a rate 
µ from all compartments, which indicates the end of their sexual activity in Switzerland. We 
accounted for reinfections and naïve infections by splitting this model. The resulting model 
(“reinfection model”) is equivalent to the main one and its structure is displayed in Figure S1.  
 
Model parameterization 
Most parameters were measured from SHCS data. The high-risk/unsafe sex ratio φ, the 
proportion of individuals out-of-care and the change in diagnosis rate over calendar year were 
estimated from published data, the infection rate β and the assortativity coefficienwere fitted 
to the incidence data by Maximum Likelihood (Supplementary Material).  
We obtained the numbers of newly susceptible individuals ρ(t) from the SHCS database and 
the proportion of HIV-infected MSM out of the SHCS. These numbers were based on new 
registrations into the cohort. We used Bayesian Poisson regression models(17, 18) to estimate 
entrance rates from these numbers. HCV treatment rates were determined separately for the 
periods 2000-2005 and 2006-2013, since treatment uptake substantially increased between 
those periods in the SHCS(19). We modeled this transition as a logistic function (see 
Supplementary material). Initial conditions were also approximated from data, namely the 
numbers of patients susceptible, infected, and on treatment for HCV at the beginning of 2000. 
We used SHCS information on self-reported unprotected sex with occasional partners to 
estimate two time-dependent high-risk recruitment parameters: i) the proportion of patients 
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who reported unsafe sex ψ(t) during their second follow-up visit, which we consider to reflect 
their sexual behavior following HIV-diagnosis; and ii) the rate σ(t) at which patients without 
unsafe sex at the begging of the follow-up, started to engage in this practice.  
We estimated the percentage of patients out-of-care by combining data from the European 
men-who-have-sex-with-men Internet survey (EMIS) (20) and a modeling study on HIV 
transmission among MSM in Switzerland (21). We found transition rates from HIV-infection 
to enrolment in care that led the model to reproduce this proportion by assuming that this rate 
reflected the increase estimated in(21). 
Uncertainty analyses were based on Latin Hypercube sampling. We sampled the transmission 
rate β, the exit rate µ and the external force of infection λ and produced combinations of these 
parameters using this technique. We then obtained model solutions for each combination to 
determine 95% confidence intervals (Supplementary Material). 
 
Interventions to reduce high-risk behavior and treatment scenarios 
We projected future HCV incidence based on hypothetical interventions that reduce high-risk 
behavior and increase treatment uptake and/or efficacy. Projections of the high-risk 
recruitment parameters were based on observed trends. Behavioral interventions included 
three scenarios: 1)Pessimistic scenario: no intervention, in which the size of the high-risk 
group grows further according to the trend observed in the SHCS over the last decade. In this 
scenario an increasing number of patients enter the high-risk group, until high-risk 
recruitment parameters duplicate the last observation; thereafter they saturate; 2)Intermediate 
scenario: health promotion or autonomous saturation leading to a stable size of the high-risk 
group. 3)Optimistic scenario: health promotion or autonomous saturation leading to a 
decreasing size of the high-risk group. In this scenario, no more patients enter the high-risk 
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category. Treatment interventions included use of DAAs and increased treatment uptake. We 
considered two scenarios for treatment uptake, according to the percentage of infected 
patients treated per year (treatment rate): 1) treatment uptake remained constant at the 
observed average between 2006 and 2013 (22% per year); and, 2) increased to 100% per year; 
i.e., the average time from infection to treatment was reduced to one year. Our model also 
compared the impact of DAAs(22, 23) with interferon-based treatments(24). The average 
duration of interferon-based treatment was assumed to be 9 months and to result in 53% 
sustained virologic response (SVR), as observed in the SHCS(19). Treatment with DAAs was 
assumed to last 3 months on average, and to result in 90% SVR, independent of HCV 
genotype(22, 23). We reported predicted incidence and prevalence curves by combining these 
scenarios.  
In a further analysis, we assessed a best-case scenario of risk behavior. In this analysis we 
accelerated the decrease in the size of the high-risk group associated with the optimistic 
scenario. We assumed that individuals in the high-risk group transit to the group without high-
risk at a rate that equals the last observed rate of transition from the group without to the 
group with high-risk behavior. This approximation aims to reflect the speed of behavioral 
change observed in the population.  
Sensitivity analysis I: Different high-risk/unsafe sex ratios 
The approximated value for the high-risk/unsafe sex ratio that we used in the main analyses 
(0.25 as observed in(13)) may not accurately reflect the reality as it does not include all sexual 
practices leading to HCV transmission. We therefore performed model fits and projections for 
all scenarios, where this ratio increased in steps of 0.05 from 0.2 to 0.4. 
 
Sensitivity analysis II: Imported infections 
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In this analysis we assumed that an increasing percentage of incident HCV infections 
observed in the high-risk group where not acquired by contact with other HIV-infected MSM 
in Switzerland (imported infections). We performed model fits and projections for all 
scenarios, where the percentage of imported infections increased from 3% to 27%. These 
values were achieved by assuming increasing external forces of infections λ in the high-risk 
group. 
Sensitivity analysis III: Protective effect of previously cleared HCV infection 
Some studies suggest that the risk of reinfection after clearance may be lower than the risk of 
infection in naïve individuals (25). We assessed the effect of this potential protective effect by 
assuming that the probability of HCV transmission given an infectious contact is lower in 
individuals who have cleared HCV than in naïve individuals. We performed model fits and 
projections for all scenarios, where the probability of reinfection was reduced by 13%, 25% 
(as in (26) ) and 50%. 
All procedures, including calibration, fitting algorithms and uncertainty analyses were 
implemented in R(27). Differential equations were solved with the R package deSolve(28, 
29). 
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Results 
Study population  
A total of 5,052 MSM were included in the analyses (Table 1). Median age at registration in 
the SHCS was 37 years [interquartile range (IQR) 31–44]. Ninety-one percent of all patients 
started ART during the follow-up time. Sex with occasional partners was reported by 
3,860(76%) MSM, of whom 1,860(48%) also reported inconsistent condom use.  
 
Model parameter estimates 
Model parameters used to reproduce observed HCV incidence in the SHCS are shown in 
Table 2. An average of 190 HCV-negative MSM newly diagnosed with HIV and without 
history of intravenous drug use were enrolled into the cohort per year (Supplementary Figure 
S2A). The proportion of patients who reported unsafe sex during their second follow-up visit 
was 5% in 2000 and increased continuously to reach 13% in 2013 (Figure 2A). The transition 
rate to unsafe sex rose from 0.05 per year in 2000 to 0.13 per year in 2012 (Figure 2B). We 
assumed that a fraction 0.25 of patients who engage in unsafe sex engage in high-risk 
behavior. This approximation reflects the ratio between the number of patients who reported 
frequent bondage, dominance/submission, sadism/masochism (BDSM) or fisting and those 
who reported unprotected anal intercourse with non-steady partners in(13). The percentage of 
patients treated for HCV was 11% before 2006, and rose to 42% between 2006 and 2013. 
Consistently, when we compared the periods 2000-2005 and 2006-2013, average treatment 
rate increased by a factor of 10: 2% per year in the earlier period versus 22% per year in the 
later period (Table 2). Finally, the exit rate estimated from patients who died or left 
Switzerland, as specified in the cohort, was 0.049 (95% CI: 0.045-0.053), which implies an 
average time of over 20 years of sexual activity. We estimated that on average 84% HIV-
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infected MSM were in care between 2000 and 2010. Associated rates of enrollment in care 
were found to be 0.45/year and 0.58/year. These rates imply times from HIV-infection to 
enrolment in care of 2.2 and 1.73 years respectively. Figure S3 shows the likelihood curve for 
the estimated rate of infection. 
 
Observed and modeled HCV incidence, 2000-2013 
Modeled HCV incidence accurately reproduces observed HCV incidence (Figure 2C). It 
increased from 0.2/100 person-years (py) in 2000 to 1.0/ 100 py in 2013.  
 
Impact of interventions to reduce high-risk sexual behavior and treatment scenarios, 
2015-2030  
Pessimistic scenario: growing size of the high-risk group 
If the spread of high-risk practices associated with HCV transmission was unchecked, the 
model predicted a steep increase in HCV incidence and prevalence. Incidence converged to 
10.7/100 py if treatment practice remained unchanged (upper panel Figure 3A). If treatment 
uptake increased considerably, incidence continued to rise at a lower rate than with the current 
treatment practice, to reach 10.4/100 py and 8.5/100 py in 2030 with and without DAAs 
respectively (upper panel Figure 3A). Interestingly, the highest predicted incidence was 
observed in the scenario with current treatment uptake and DAAs. A combination of two 
factors explains this behavior: Firstly, short duration effective treatments lead to rapidly cured 
infections, which in turn results in an enlarged size of the susceptible group; and secondly, the 
treatment rate is not large enough to contain transmission. This outcome is observed in all 
scenarios.  
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Prevalence also increased rapidly in this scenario. Without change in treatment uptake, it was 
above 36% in 2030 irrespective of the type of treatment. But if treatment uptake increased 
considerably, prevalence in 2030 was 23.1% and 11% without and with DAAs respectively 
(lower panel Figure 3A). The model also predicted that in 2030 reinfection will account for at 
least 44% of all incident infections (versus 3.6% in 2015; Table S1) 
Intermediate scenario: stable size of the high-risk group 
Stabilization of high-risk behavior without change in treatment uptake led to a rapidly 
saturated incidence at around 2.6/100 py if treatment uptake did not change. If treatment 
uptake increased considerably, DAAs led to a continuous decline in incidence, reaching 
0.5/100 py in 2030 (upper panel Figure 3B). The benefit of DAAs compared to interferon-
based therapy was largest in this case. Prevalence displayed a similar pattern. It stabilized at 
around 12.7% if treatment uptake did not change, and decreased considerably to reach 0.9% at 
the highest treatment uptake with DAAs (lower panel Figure 3B). The model also predicted 
that in 2030 reinfection will account for at least 23% of all incident infections (Table S1). 
Optimistic scenario: decreasing size of the high-risk group 
A reduction in the frequency of high-risk practices associated with HCV transmission led to 
an immediate decrease in incidence, regardless of treatment uptake and type of treatment 
(upper panel Figure 3C). In this scenario, introducing DAAs had only a modest influence on 
incidence and prevalence. As expected, the minimal incidence and prevalence predicted in 
this study were achieved in this scenario when DAAs were introduced at the highest treatment 
uptake (incidence: 0.2/100 py, prevalence: 0.4% in 2030). The model predicted that in 2030 
reinfection will account for at least 7.6% of all incident infections (Table S1). 
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Best-case scenario: rapidly decreasing size of the high-risk group 
In this scenario, the model predicted an immediate steep decline in HCV incidence (upper 
panel Figure 4A). In 2025 incidence saturated at 0.2/100 py irrespective of treatment 
interventions. Prevalence also declined considerably in this scenario. In ranged between 2.5% 
and 0.4% in 2030 (lower panel Figure 4A). 
Figure 4B shows HCV incidence and prevalence associated with different scenarios of high-
risk behavior when assuming treatment with DAAs and current treatment rate. In all 
scenarios, incidence was more sensitive to the considered changes in treatment uptake than to 
changes in treatment efficacy (Figure 3). Trends for high-risk recruitment parameters in the 
first two behavioral scenarios are displayed in Figure S4. Table S2 shows changes in high-risk 
behavior associated with each scenario. 
 
Sensitivity analysis I: Different high-risk/unsafe sex ratios 
Projected HCV incidences with all interventions assuming increasing high-risk/unsafe sex 
ratios (i.e., increasing the proportion of patients with unsafe sex who also engage in high-risk 
behavior) are shown in supplementary Figure S5. In the pessimistic case scenario of risk 
behavior, the model predicted higher incidence and prevalence with increasing high-
risk/unsafe sex ratios. Incidence in 2030 ranged from 8.2/100 py to 20.5/100 py and 
prevalence from 10.6% to 51.2% . with a ratios of 0.2 and 0.4 respectively (left panels Figure 
S5). Consistently, in the intermediate and optimistic scenarios of risk behavior, predicted 
incidence stabilized at higher values as high-risk/unsafe sex ratios increased (center and right 
panels Figure S5). Despite these differences, the effect of all intervention was equivalent to 
that described in the main analysis. 
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Sensitivity Analysis II: Imported infections 
Behavioral and treatment interventions were also effective at decreasing HCV incidence and 
prevalence when the proportion of infections assumed to be imported increased. When this 
proportion was set to be maximum (27%) in the intermediate scenario of risk behavior, 
increased treatment uptake and efficacy led to incidence and prevalence to reach 0.7/100 py 
and 1.1% in 2030 respectively (Table S3). The goodness of the fit decreased as more 
infections observed in the high-risk group were assumed to be imported, suggesting a 
predominate role of domestic transmission. Worsening fits may lead to unrealistic projections, 
especially in the pessimistic scenario because the model becomes less capable of reproducing 
the observed increase in incidence.  
 
Sensitivity Analysis III: Protective effect of previously cleared HCV infection 
Predicted HCV incidence and prevalence decreased as the reduction in reinfection probability 
increased (Table S4). Incidence and prevalence displayed the same pattern observed in the 
main analysis (Figure S6). In the pessimistic scenario, with a 25% reduction in reinfection 
probability, treatment with DAAs at the highest treatment uptake led to 5.5/100 py incidence 
(versus 8.5/100 py in the main analysis) and 7.6% prevalence (versus 11.0% in the main 
analysis). Despite these variations, the effect of all intervention was equivalent to that 
described in the main analysis, even when the protective effect was strong.  
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Discussion 
We reconstructed the HCV epidemic among HIV-infected MSM in Switzerland between 2000 
and 2013 using a mathematical transmission model based on two risk groups. We used this 
model to predict the future course of HCV incidence and prevalence in HIV-infected MSM. 
Different modeled scenarios based on hypothetical behavioral and treatment interventions 
showed that prevention of high-risk behavior alone could result in considerably reduced HCV 
transmission.  
The model showed that substantially increasing only treatment uptake would more effectively 
reduce HCV incidence and prevalence than substantially increasing only treatment efficacy. 
There are fewer contraindications to DAAs-based treatments than to interferon-based 
treatments, so DAAs-based treatments may improve uptake. The model predicts that if high-
risk behavior continues to increase according to the trends observed during the last decade, 
HCV incidence will continue to rise, despite increasing treatment uptake and efficacy. 
However, stabilization of high-risk behavior combined with a considerable increase in 
treatment uptake and efficacy could effectively reduce HCV incidence and prevalence. 
Moreover, the benefit of DAAs over IFN-based therapy was highest in this stable scenario 
when assuming high treatment uptake. Reduction in high-risk behavior could lead to a rapid 
decline in incidence within the next few years, independently of improved treatment uptake or 
efficacy. The model predicted that reinfections will account for an increasing proportion of all 
incident infections in the future. This is in line with recent studies that reported high rates of 
reinfection (30)(31). 
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Strengths and limitations 
A major strength of our analysis is that we estimated most model parameters directly by using 
patient level data from the SHCS(10, 15). Most parameters corresponded to a single 
population, so they were internally consistent. The inclusion of data on the evolution of sexual 
behavior among HIV-infected MSM over the last decade was an additional strength of our 
model. This data reveal heterogeneity(32), which we captured by splitting the population into 
two risk behavior groups.  
 
Due to the lack of data on specific high-risk practices, we had to assume that the proportion of 
people with high-risk behavior was a constant fraction of the population that engages in 
unsafe sex. We believe this is a reasonable approximation to reality which allowed us to take 
advantage of the available data on sexual behavior. This quantity was based on published 
observations(13) which may have led to an underestimation of this fraction as it does not 
include all practices that are believed to result in HCV transmission. However, a sensitivity 
analysis which considered several values of this parameter, resulted in concordant predictions. 
Another limitation was that we did not explicitly model the link between sexual behavior and 
recreational intravenous drug use, which is increasingly recognized as a risk factor for HCV 
transmission among MSM(12, 33) and may contribute to the HCV epidemic. We did not 
include HIV-uninfected MSM in the modeled population, but we think this was reasonable: a 
recent Swiss survey showed that the prevalence of HCV in HIV-uninfected MSM was only 
0.4%, thus not higher than in the general population(34). Our approximation was based on the 
fact that there is no evidence of boosted HCV transmission among HIV-negative MSM. The 
reason why HCV transmission seems to be confined to HIV-infected MSM is unknown. 
Serosorting (the practice of using HIV status as a decision-making point in choosing sexual 
partners) is common, but not generalized (35) and its role in the spread of HCV among HIV-
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infected MSM remains uncertain. Further factors including HIV-mediated impairment of 
mucosal immunity which is often not completely restored during ART may also play a role. 
Importantly, the scale-up of HIV pre-exposure prophylaxis may reduce serosorting, which in 
turn could result in an HCV transmission bridge from HIV-positive to HIV-negative MSM.  
Little is known about risk behavior patterns and demographics of people with undiagnosed 
HIV infections. However, 80% of HIV-infected MSM living in Switzerland are estimated to 
be enrolled in the SHCS (16). Therefore, the data we used to parameterize this model is likely 
to be representative for this population.  
The main model assumed a constant external force of infection. Although the frequency of 
drugs injection among MSM in the SHCS was low (only 2.5% ever reported) and stable over 
the study period (results not shown), which supports our assumption, we undertook a 
sensitivity analysis to evaluate the impact of increasing the external force of infection in the 
high-risk group. These increases are equivalent to more infections acquired by high-risk 
contacts outside the modeled population (imported infections). The model predictions 
suggested that behavioral and treatment interventions can effectively reduce incidence and 
prevalence even when the number of imported infections is large. Our conclusions also 
remained unchanged when assuming that HCV clearance reduces the risk of subsequent 
infections (protective effect). In this study, we did not explore alternative explanations for 
increased HCV transmissions over time, such as the emergence of more transmissible HCV 
strains. However, previous phylogenetic analyses revealed that many different HCV strains 
were involved in its spread among HIV-infected MSM(11, 36), so the emergence of a 
particularly transmissible HCV strain is unlikely to be the main driver of the epidemic. 
Finally, assuming that risk behavior will continue to increase at the speed it has over the last 
years (as we did in the pessimistic scenario) may have led to unrealistically large sizes of the 
population with high-risk behavior and resulted in a very high prevalence for the pessimistic 
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scenario. This and the best-case scenario are extreme cases that bound the possible future 
outcomes of the HCV epidemic. Our results may not apply to populations of HIV-infected 
MSM where HCV incidence has not increased, since these populations may not have the same 
demographic, clinical and behavioral characteristics (37) as the population we studied. But 
HCV incidence has recently increased among HIV-infected MSM in many settings as 
synthesized in a meta-analysis (9). 
 
In this study, we did not use viral sequence data to trace HCV transmissions. A recently 
published phylogenetic analysis in the SHCS(38) revealed that people with closely related 
HIV viruses were more likely to acquire HCV infection if their phylogenetic-neighbours were 
HCV-infected. These HIV and HCV transmission networks within the SHCS underscore the 
role of domestic HCV transmission linked to sexual risk behavior. Therefore, public health 
interventions might reduce HCV transmission even if these are only implemented locally. 
 
Comparison with other studies 
We believe ours is the first published modeling study to (i) use data on changes in high-risk 
behavior to account for changes in HCV incidence among HIV-infected MSM, (ii) to evaluate 
the effects of trends in high-risk behavior on the course of the HCV epidemic, independent of 
treatment intensification, and (iii) to incorporate longitudinal data on sexual behavior and 
routine HCV screening together with HCV treatment uptake and outcomes. Martin et al. (39) 
recently modeled the HCV epidemic among HIV-diagnosed MSM in the UK and found that 
scaling-up DAAs in this setting could substantially reduce HCV prevalence without 
behavioral interventions, but Martin et al studied a population with stable primary HCV 
incidence, while primary HCV incidence has increased in the SHCS and in other settings over 
the last decade (3)(9). Martin et al did not include data on the evolution of high-risk behavior 
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or assess the role of changing high-risk behavior, independent of treatment intensification. 
Because changes in high-risk behavior drive the surging HCV epidemic and are a key target 
for interventions, we based our predictions on potential scenarios of high-risk behavior. In 
contrast with the study by Martin et al, our results suggest that in settings where HCV 
incidence is rising, scaling-up treatment cannot revert the HCV epidemic if high-risk behavior 
continues to spread as it has over the last decade. 
Implications of Findings 
Our model suggests that the most effective strategy for controlling the HCV epidemic among 
HIV-infected MSM is to adopt health promotion interventions that limit high-risk behavior. 
Targeted interventions to curb the HCV epidemic, such as increasing access to treatment, are 
effective if accompanied by interventions or autonomous saturation that slow the spread of 
high-risk behavior. Of note, self-reported unsafe sex does not reflect all high-risk sexual 
practices associated with HCV transmission that are not recorded in the SHCS. Self-reported 
unsafe sex rather served as a proxy for high-risk behavior. The good fit of the model 
predictions to the incidence data suggests that self-reported unsafe sex is associated with other 
high-risk sexual practices. Trends in self-reported unsafe sex might therefore predict the 
future course of HCV infections and guide interventions to reduce HCV incidence. The 
results of this study could be used to inform public health policy intended to prevent HCV 
transmission among HIV-infected MSM.  
The validity and scope of our findings must be determined in clinical trials or observational 
studies. These model projections are based on hypothetical representative outcomes of 
interventions to reduce high-risk behavior (pessimistic, intermediate, optimistic and best), but 
real world interventions are likely to cluster around the intermediate scenario. Cost-
effectiveness analyses that consider realistic outcomes for behavioral interventions are also 
Page 21 of 53
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
22 
 
 
 
required to guide implementation of public health interventions intended to reduce 
transmission of HCV among HIV-infected MSM. 
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 Table 1. Characteristics of all MSM registered in the Swiss HIV Cohort Study  
who were included in the parameterisation of the model.   
Total number of patients 5,052 
Age at registration [median(IQR)] 37 (31 - 44) 
Follow up time [years, median(IQR)] 7.8 (3.6 - 14.9) 
ART   
     Yes 4,619 (91.4%) 
     No 433 (8.6%) 
CD4 cell count at ART start [cells/μl, median(IQR)] 268 (156 -389) 
Viral load at ART start [ log10 copies/ml, median (IQR) ] 4.8 (4.2 - 5.3) 
Intravenous drug use 127 (2.5%) 
Information on sexual partners   
Sex with Stable partners [N(%)]   
          Yes 3,655 (72.3%) 
          No  1,257 (24.9%) 
          Refuse to answer 91 (1.80%) 
          Missing  49 (0.97%) 
Condom use with stable partner [N(%)]   
     Inconsistent 2,080 (56.9%) 
     Refuse to answer 29 (0.8%) 
     Missing 1 (0%) 
Sex with occasional partners [N(%)]   
           Yes 3,860 (76.4%) 
           No  975 (19.3%) 
          Refuse to answer 168 (3.3%) 
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          Missing 49 (1.0%) 
Condom use with occasional partner [N(%)]   
     Inconsistent  1,860 (48.1%) 
     Refuse to answer 40 (1.0%) 
     Missing 2 ( 0.0%) 
Only patients with available questionnaires on sexual partners who were 
followed beyond 2000 were included 
ART: antiretroviral therapy   
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Table 2. Model parameters used to reproduce the incidence observed between 2000 and 2013. 
Parameter Definition Value Functional form Source 
ω Rate of enrolment in care (from HIV-
infection; per year) 
    0.45  before 2005 
    0.58  after   2005 
 Estimation using 
data from (21) 
ρ(t) New HCV-uninfected MSM rate 
a,b
 
(individuals per year) 
[135 - 257] Splines smoothing of a series  
of yearly rates 
SHCS 
ψ(t) Proportion of individuals with unsafe sex 
at entry
c 
 3.2	× 10		
	 < 3.8 
	6.1 × 10	 − 1.6	× 10			 + 2.5	× 10		 							
− 	7.2	× 10		
	0.3 < 
< 13.5 
SHCS 
φ High-risk/unsafe sex ratio 0.25  [12] 
σ(t) Rate at which individuals start to have 
unsafe sex (per year)
c 
 4.1	× 10	 + 	2		× 10			 − 	1.4	× 10	
+ 		1.2	× 10 
SHCS 
β Infection rate (95% CI) (per year)  5.1 (4.3 – 5.7)  Fit 
α Proportion of patients who clear infection 
after treatment 
e 
0.53  SHCS 
 [17] 
η 1/average treatment duration (per year) 4/3  SHCS 
λ External force of infection x 10
-3 f
(per 2.3   SHCS 
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 Abbreviations: MSM, Men who have Sex with Men; SHCS, Swiss HIV Cohort Study 
a
Rates were obtained applying Bayesian Poisson regression models with non-parametric smoothing priors using the R package INLA [16]. 
b
Scaled to the HIV-infected MSM population in Switzerland assuming that 80% of all individuals in this population enrol in the SHCS. 
c
The origin is 2000. 
d
Ratio between the number of patients who reported  frequent bondage, dominance/submission, sadism/masochism or fisting and those who reported 
unprotected anal intercourse with non-steady partners. The approximated ratio between patients who reported skin damage with bleeding and those who 
reported unprotected anal intercourse with non-steady partners is 0.23. 
e
Weighted average according to time from diagnosis to treatment initiation. 
f
1999-2000 average incidence rate. 
year) 
μ Exit rate (95% CI) 0.049 (0.045 - 0.053)  SHCS 
γ(t), γ'(t) Rate of treatment for each risk group 
(per year) 
[0.02 - 0.22] 0.2/(1+e
-t+2006
)+0.02 SHCS 
S2000+ S’2000
b,g
 Initial number uninfected patients 1,552  SHCS 
I2000
b,g
 Initial number of infected patients 8  SHCS 
T2000
b,g
 Initial number of patients on treatment 0  SHCS 
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g
Initial value in year 2000 
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Figure legends 
Figure 1. Model structure 
HCV transmission dynamics in HIV-infected MSM. Individuals are distributed in groups 
according to their risk behavior (without and with high-risk) and enrolment in care ( “i”: in-
care and “o”: out-of-care). Individuals switch from the group without high-risk to the group 
with high-risk at a rate φσ(t) and from the group out-of-care to the group in-care at a rate ω(t). 
New individuals enter the susceptible categories () at an overall rate ρ(t). A fraction φ(t) are 
assigned to the high-risk group. Susceptible individuals may be infected (I) by an external 
force of infection λ that accounts for infections not acquired by contacts within the modelled 
population. Individuals within the high-risk group may also infect each other at an infection 
rate β. Individuals with spontaneous HCV-clearance remain susceptible. Infected individuals 
without spontaneous clearance start HCV-treatment (T) at a rate γ(t). Treatment lasts on 
average 1/η and results in HCV-clearance for a proportion α of all treated patients. Individuals 
exit the system at a rate µ from all compartments.  
 
Figure 2. High-risk recruitment parameters and HCV incidence 
High-risk recruitment parameters and HCV incidence measured in the Swiss HIV Cohort 
Study (SHCS) between 2000 and 2013. Panel A. proportion of new individuals who have 
unprotected sex with occasional partners (unsafe sex). Panel B. rate at which individuals start 
to have unsafe sex; (black stars: observed, continuous black line: functional fit; see Table 2). 
The model assumed that a fraction of the patients with unsafe sex also engage in high-risk 
behavior, which can result in HCV transmission. Panel C. HCV incidence rates observed in 
the SHCS (green dots and error bars) and obtained with our transmission model (continuous 
blue line; shaded: 95% confidence intervals).  
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Figure 3. Projected HCV incidence and prevalence 
Projected HCV incidence and prevalence in HIV-infected men who have sex with men 
(MSM) assuming that the size of the high-risk group grows (panels (A)), and health 
promotion or autonomous change leading to: i) decreasing size of the high-risk group, (panels 
(B)) and ii) decreasing size of the high-risk group (panels (C)). Two scenarios of future 
treatment uptake were included: 1) treatment rate constant at the average between 2006 and 
2013 (22% per year, continuous lines) or 2) increased treatment rate (100% per year, dashed 
lines). Two treatment alternatives are displayed: Second generation DAAs regimens (red) and 
the current standard of care (blue). Dashed, grey, vertical lines indicate the beginning of the 
projection period. 
Figure 4. Projected HCV incidence and prevalence in the best-case scenario of risk 
Behavior (A), and in all scenarios of high-risk behavior assuming treatment with DAAs 
with current treatment uptake (B). 
Panel A. Projected HCV incidence (upper panel) and prevalence (lower panel) in HIV-
infected men who have sex with men (MSM) assuming that no additional individuals enter 
the high-risk group and that individuals in the high-risk group transit to the group without 
high-risk at a rate that equals the last observed rate of transition from the group without high-
risk behavior to the group with high-risk behavior. Two scenarios of future treatment uptake 
were included: 1) treatment rate constant at the average between 2006 and 2013 (22% per 
year, continuous lines) or 2) increased treatment rate (100% per year, dashed lines). Two 
treatment alternatives are displayed: Second generation DAAs regimens (red) and the current 
standard of care (blue). Dashed, grey, vertical lines indicate the beginning of the projection 
period. Panel B. Effect of reductions in high-risk behavior when assuming treatment with 
DAAs and current treatment rate. 
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Hepatitis C transmission model 
 
We adopted the following system of ordinary differential equations (ODE) to model 
transmission of hepatitis C virus among HIV-infected men who have sex with men who do 
not inject drugs (see Figure 1 and heading HCV transmission model in the Subjects and 
Methods section).  
 
𝑤𝑤𝑤ℎ𝑜𝑜𝑤 ℎ𝑤𝑖ℎ − 𝑟𝑤𝑟𝑟 𝑏𝑏ℎ𝑎𝑎𝑤𝑜𝑜𝑟
⎩
⎪
⎪
⎪
⎪
⎨
⎪
⎪
⎪
⎪
⎧
𝑑𝑆𝑜′
𝑑𝑤
= �1 −𝜑𝜑(𝑤)�𝜌(𝑤) − 𝜑𝜑(𝑤) max�0, ?̃?𝑜� − 𝜔(𝑤)𝑆𝑜′– 𝜆𝑆𝑜′ −  𝜇𝑆𝑜′                      𝑑𝑆𝑖′
𝑑𝑤
= −𝜑𝜑(𝑤) max�0, ?̃?𝑖� + 𝜔(𝑤)𝑆𝑜′ + 𝛼𝛼𝛼′ − 𝜆𝑆𝑖′ −  𝜇𝑆𝑖′                                      𝑑𝐼𝑜′
𝑑𝑤
= −𝜑𝜑(𝑤) max(0, 𝐼𝑜) − 𝜔(𝑤)𝐼𝑜′ + 𝜆𝑆𝑜′ − 𝜇𝐼𝑜′
𝑑𝐼𝑖
′
𝑑𝑤
= −𝜑𝜑(𝑤) max(0, 𝐼𝑖) + 𝜔(𝑤)𝐼𝑜′ − 𝛾(𝑤)𝐼𝑖′ + (1 − 𝛼)𝛼𝛼′ + 𝜆𝑆𝑖′ − 𝜇𝐼𝑖′                                                𝑑𝛼′
𝑑𝑤
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⎩
⎪
⎪
⎪
⎪
⎨
⎪
⎪
⎪
⎪
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= 𝜑𝜑(𝑤)𝜌(𝑤) + 𝜑𝜑(𝑤) max�0, ?̃?𝑜� − 𝜔(𝑤)𝑆𝑜 − 𝛽𝑆𝑜( 𝐼𝑜+𝐼𝑖)Ñ  – 𝜆𝑆𝑜 −  𝜇𝑆𝑜                         𝑑𝑆𝑖
𝑑𝑤
= 𝜑𝜑(𝑤) max�0, ?̃?𝑖� + 𝜔(𝑤)𝑆𝑜 − 𝛽𝑆𝑖( 𝐼𝑜+𝐼𝑖)Ñ + 𝛼𝛼𝛼 − 𝜆𝑆𝑖 −  𝜇𝑆𝑖                                    𝑑𝐼𝑜
𝑑𝑤
= 𝜑𝜑(𝑤) max(0, 𝐼𝑜) − 𝜔(𝑤)𝐼𝑜 + 𝛽𝑆𝑜( 𝐼𝑜+𝐼𝑖)Ñ + 𝜆𝑆𝑜 − 𝜇𝐼𝑜
𝑑𝐼𝑖
𝑑𝑤
= 𝜑𝜑(𝑤) max(0, 𝐼𝑖) + 𝜔(𝑤)𝐼𝑜 + 𝛽𝑆𝑖( 𝐼𝑜+𝐼𝑖)Ñ − 𝛾(𝑤)𝐼𝑖 + (1 − 𝛼)𝛼𝛼 + 𝜆𝑆𝑖 − 𝜇𝐼𝑖                                                                            𝑑𝛼
𝑑𝑤
= 𝜑𝜑(𝑤) max�0,𝛼�� +  𝛾(𝑤)𝐼𝑖 − 𝛼𝛼 − 𝜇𝛼
 
 
Where: Ñ =   𝜃(𝑆𝑜′ + 𝑆𝑖′ + 𝐼𝑜′ + 𝐼𝑖′ + 𝛼′) + (𝑆𝑜 + 𝑆𝑖 + 𝐼𝑜 + 𝐼𝑖 + 𝛼). The transformations ?̃?𝑜 =
𝑆𝑜
′ + 𝜑−1
𝜑
𝑆𝑜 , 𝐼𝑜 = 𝐼𝑜′ + 𝜑−1𝜑 𝐼𝑜, 𝛼� = 𝛼′ + 𝜑−1𝜑 𝛼, ?̃?𝑖 = 𝑆𝑖′ + 𝜑−1𝜑 𝑆𝑖  and 𝐼𝑖 = 𝐼𝑖′ + 𝜑−1𝜑 𝐼𝑖 were 
introduced to ensure that ratio between the population in the high-risk group remains a 
constant proportion  𝜑 of those who would be classified to be at risk of unsafe sex. We 
assumed that the rate of potentially infectious contacts depends on the density of individuals 
with high-risk behaviour in a wider population. In this population, individuals in the group 
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without high-risk behaviour are weighted by the parameter θ≤1, which we term assortativity 
coefficient. Model fitting procedures led to determine the best value for this parameter to be 1.  
Definitions for the variables and parameters included in this model as well as a detailed 
description of the underlying transmission dynamics can be found in the methods section of 
the paper. All parameter values are shown in Table 2. 
 
Rate of entrance of new HCV-uninfected MSM: Rates were obtained applying Bayesian 
Poisson regression models using the R package INLA (1, 2). The INLA method uses the 
Laplace approximation to perform approximate Bayesian inference. Figure S2B displays the 
normalize Pearson residuals for this regression. This pattern does not exhibit a trend, which 
suggests that the regression is unbiased.  
 
Treatment rate 2000-2013: As described in the Methods section, we determined HCV 
treatment rates separately for the periods 2000-2005 and 2006-2013 because treatment uptake 
substantially increased between those periods in the SHCS. We used a logistic function to 
model this transition. The maximum value of this function was the treatment rate measured 
for the later period (22% per year) and the minimum value was that measured for the earlier 
period (2% per year). We assumed that the sigmoid's midpoint was reached in 2006 and that 
the steepness of the curve was 1. The resulting functional form for the treatment rate was:   
γ(t)  =  0.2
1+e−t+2006
+ 0.02. 
Maximum likelihood Estimation to fit the transmission model: using HCV-incidence data 
from the SHCS 
We used Maximum Likelihood Estimation (MLE) to fit the infection rate β. We calculated the 
likelihood of patient-level incidence data given our transmission model. For this purpose, we 
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split the data and the simulation period (2000-2013) into monthly steps. For every time step 
we compared the incidence observed in the data with that produced using the model. 
Individuals who seroconvert contribute to the total likelihood L with the probability of 
becoming infected at their individual time of infection; and individuals who never seroconvert 
contribute to L with the (cumulative) probability of being uninfected at the end of their 
individual exposure periods.  
L is then given by: 
𝐿 =   �𝐿𝑖𝑛
𝑖=1
=  �ℎ(𝑤𝑖)𝛿𝑖(1 − 𝐹(𝑤𝑖))𝑛
𝑖=1
 
Where: i indexes the n individuals at risk of HCV-infection; ti is the time the individual i was 
exposed to HCV-infection; and h(ti) the evaluation of the hazard function at that time which 
we approximated to 𝛽 𝑆𝑜(𝑡𝑖)+𝑆𝑖(𝑡𝑖) 
𝑆𝑜
′ (𝑡𝑖)+𝑆𝑖′(𝑡𝑖)+𝑆𝑜(𝑡𝑖)+𝑆𝑖(𝑡𝑖) 𝐼𝑜(𝑡𝑖) + 𝐼𝑖(𝑡𝑖)Ñ +  𝜆. δi is 1 if the individual i 
experiences the event and 0 otherwise. F(ti) is the cumulative distribution function of time to 
HCV infection, i.e., F(ti)=∫ 𝑓(𝑤)𝑡𝑖0 𝑑𝑤, where f(t) is the probability density function of time to 
HCV infection.  
 
The log-likelihood is then given by:  
𝑙𝑙(𝐿) =  �{𝛿𝑖 ln�ℎ(𝑤𝑖)� − 𝐻(𝑤𝑖)}𝑛
𝑖=1
  
By means of this relationship we minimised the negative log-likelihood (NLL) of observed 
patient-level incidence data from the SHCS data given the transmission model. The final 
value for β is reported in Table 2. We used a likelihood curve to estimate confidence intervals 
for this parameter. Figure S3 shows the likelihood curve and the corresponding confidence 
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interval. We performed the optimizations with the R package optim (3)  and solved the 
systems of differential equations with the R package deSolve (4, 5). 
Increasing high-risk/unsafe sex ratios led to lower estimates of the infection rate. Higher 
ratios also resulted in slightly improved model fits, but the maximum difference in negative 
log-likelihood did no exceed 0.5 (results not shown). 
 
Uncertainty of Model Predictions 
In order to assess how the uncertainty of the model parameters estimated by MLE affect the 
model solutions and predictions (of future HCV incidence), we used Latin Hypercube 
Sampling (LHS). Specifically, we sampled the infection rate β from a normal distribution that 
corresponds with its likelihood curve (Figure S3). We sampled the exit rate μ and the external 
force of infection λ from lognormal distributions depicted by the mean and the standard error 
estimated from the SHCS data (Table 2). We generated the sample of parameters’ 
combinations for running the simulation model using the R package clhs (6) and obtained 
incidence predictions for each of these combinations to determine 95% confidence intervals. 
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Supplementary Figures 
Figure S1. Structure of the “reinfection model”. Super indices 2 indicate compartments 
associated with reinfections: Susceptible to reinfections, reinfected and on treatment for a 
reinfection (see also see Figure 1 in the main text). 
 
 
  
Page 46 of 53
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
 
 
7 
 
 
Figure S2. A. Rate of entrance of new HCV-uninfected MSM with no history of injecting 
drug use calculated from the new registrations into the SHCS between 2000 and 2013 using 
Bayesian Poisson regression models (green dots); Smooth entry rates (solid black line, 
shaded: 95% confidence intervals). B. Normalized Pearson residuals for this regression 
model. 
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Figure S3. Likelihood curve for the infection rate (β= 5.1 (4.3 – 5.7)) fitted using MLE 
(grey, dotted lines: 95% credible intervals). NLL: negative log likelihood. 
 
Figure S4. Trends for high-risk recruitment parameters 
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Figure S5. Projected HCV incidence in HIV-infected men who have sex with men (MSM) 
for different values of the high-risk/unsafe sex ratio φ, assuming that the size of the high-risk 
group grows (panels (A)), and health promotion or autonomous change leading to: i) 
decreasing size of the high-risk group, (panels (B)) and ii) decreasing size of the high-risk 
group (panels (C)). Two scenarios of future treatment uptake were included: 1) treatment rate 
constant at the average between 2006 and 2013 (22% per year, continuous lines) or 2) 
increased treatment rate (100% per year, dashed lines). Two treatment alternatives are 
displayed: Second generation DAAs regimens (red) and the current standard of care (blue). 
Dashed, grey, vertical lines indicate the beginning of the projection period. 
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Figure S6. Projections assuming a protective effect of previously cleared HCV infections. 
Reduction in reinfection probability = 25% (similar to the assumption in [Martin, Journal of 
Theoretical biology, 2011]). 
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Supplementary tables 
 
Table S1. Percentage of incident infections that are reinfections. 
 
 
Table S2. Changes in high-risk behaviour. 
 
Table S3. Sensitivity analysis on the external force of high-risk related HCV-infections 
(imported infections). 
 
 
Table S4. Sensitivity analysis assuming a protective effect of previously cleared HCV 
infections. 
 
Scenario of risk behaviour
Calendar year 2015 2020 2030 2015 2020 2030 2015 2020 2030
IFN + current treatment uptake 3.6% 16.5% 44.0% 3.6% 24.6% 44.5% 3.6% 33.9% 58.8%
DAAs + current treatment uptake 3.6% 26.6% 58.1% 3.6% 36.0% 56.9% 3.6% 45.9% 66.1%
IFN + higher treatment uptake 3.6% 22.3% 57.0% 3.6% 30.5% 44.6% 3.6% 36.3% 31.6%
DAAs + higher treatment uptake 3.6% 26.2% 57.0% 3.6% 32.6% 23.3% 3.6% 35.4% 7.6%
Pessimistic Intermediate Optimistic
Pessimistic 75% 184%
Intermediate -2% 4%
Optimistic -26% -58%
* with respect to the value in 2015
Negative increase means decrease
5-year increase 15-year increase Scenario of high behaviour
Increase in proportion with high-
risk behaviour*
A. Incidence per 100 person-years (2030)
Scenario of risk behaviour
Percentage of imported infections* 3% (Main model) 6% 12% 27% 3% (Main model) 6% 12% 27% 3% (Main model) 6% 12% 27%
IFN + current treatment uptake 10.7 10.5 9.9 8.6 2.3 2.2 2.1 1.9 0.6 0.6 0.6 0.5
DAAs + current treatment uptake 13.7 13.3 12.3 10.1 2.8 2.8 2.6 2.1 0.7 0.7 0.7 0.6
IFN + higher treatment uptake 10.4 9.6 8.0 4.8 1.6 1.5 1.3 1.0 0.4 0.4 0.4 0.4
DAAs + higher treatment uptake 8.5 7.1 4.6 2.3 0.5 0.6 0.6 0.7 0.2 0.3 0.3 0.4
B. Prevalence (2030)
Scenario of risk behaviour
Percentage of imported infections* 3% (Main model) 6% 12% 27% 3% (Main model) 6% 12% 27% 3% (Main model) 6% 12% 27%
IFN + current treatment uptake 39.9% 39.2% 37.7% 33.6% 13.6% 13.4% 12.8% 11.4% 6.1% 6.0% 5.8% 5.4%
DAAs + current treatment uptake 36.8% 36.0% 34.1% 29.1% 11.7% 11.3% 10.6% 8.8% 4.5% 4.4% 4.2% 3.7%
IFN + higher treatment uptake 23.1% 21.6% 18.4% 11.8% 4.9% 4.5% 3.9% 3.1% 1.5% 1.5% 1.5% 1.5%
DAAs + higher treatment uptake 11.0% 9.3% 6.3% 3.3% 0.9% 0.9% 1.0% 1.1% 0.4% 0.4% 0.5% 0.6%
*Percentage of all incident infections in de high-risk population in care in 2013.
Pessimistic Intermediate Optimistic
Pessimistic Intermediate Optimistic
A. Incidence per 100 person-years (2030)
Scenario of risk behaviour
Reduction in reinfection probability* 0% (Main model) 13% 25% 50% 0% (Main model) 13% 25% 50% 0% (Main model) 13% 25% 50%
IFN + current treatment uptake 10.7 10.5 10.3 9.5 2.3 2.2 2.2 2.0 0.6 0.6 0.5 0.5
DAAs + current treatment uptake 13.7 13.2 12.6 10.9 2.8 2.7 2.6 2.1 0.7 0.7 0.6 0.5
IFN + higher treatment uptake 10.4 9.5 8.6 6.4 1.6 1.4 1.2 0.9 0.4 0.3 0.3 0.3
DAAs + higher treatment uptake 8.5 6.9 5.5 3.4 0.5 0.5 0.4 0.3 0.2 0.2 0.2 0.2
B. Prevalence (2030)
Scenario of risk behaviour
Reduction in reinfection probability* 0% (Main model) 13% 25% 50% 0% (Main model) 13% 25% 50% 0% (Main model) 13% 25% 50%
IFN + current treatment uptake 39.9% 39.4% 38.8% 37.1% 13.6% 13.4% 13.1% 12.2% 6.1% 5.9% 5.7% 5.2%
DAAs + current treatment uptake 36.8% 36.0% 35.0% 31.9% 11.7% 11.2% 10.7% 9.3% 4.5% 4.3% 4.0% 3.3%
IFN + higher treatment uptake 23.1% 21.6% 20.0% 16.1% 4.9% 4.4% 3.9% 3.0% 1.5% 1.4% 1.3% 1.1%
DAAs + higher treatment uptake 11.0% 9.2% 7.6% 5.0% 0.9% 0.8% 0.7% 0.6% 0.4% 0.4% 0.4% 0.4%
* with respect to first infection
Pessimistic Intermediate Optimistic
Pessimistic Intermediate Optimistic
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